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ARTICLE INFO Misoprostol is licensed to treat  gastric ulcers but now it is widely used 
for a variety of indications in osbtetrics and gynecology. This is called ‘off-
label’ use.  Misoprostol is cheap, stable at room temperature and easily 
to access it. Available in tablet form, it can be administred vaginally, 
rectally, sublingually and bucally. This review explains benefit and risk of 
misoprostol in obstetric and gynecology field.
Misoprostol dilisensikan untuk mengobati ulkus gaster.  Namun saat ini digunakan luas untuk berbagai 
macam indikasi dalam bidang obstetrik dan ginekologi.  Penggunakan ini dikenal dengan nama “off –
label.”  Misoprostol adalah obat yang murah, stabil pada suhu ruangan dan mudah diperoleh.  Tersedia 
dalam bentuk tablet, dan dapat diberikan secara intravagina, rektal, sublingual dan bukal.  Tinjauan ini 
akan menjelaskan manfaat dan resiko misoprostol didalam bidang obstetri dan ginekologi.
INTRODUCTION
Misoprostol is a synthetic prostaglandin 
E1 analogue which  has a capability to pro-
duce a dose-related inhibition of gastric acid 
and pepsin secretion, and to enhance mucosal 
resistance to injury so that  this drug has been 
approved  by Food and Drug Administration 
in the United States   (US) for the prevention 
and treatment gastric ulcers resulting from 
chronic administration of non-steroidal an-
ti-inflammatory drugs.1 However, In the prac-
tice of obstetrics and gynecology, misoprostol 
has been used off-label for several indication, 
including abortion, induction of labor, cervi-
cal ripening before surgical procedures, and 
the treatment of postpartum hemorrhage.2-5 
Due  to misoprostol has so many benefit in 
the practice of obstetrics and gynecology, it 
is recommended by World Health Organi-
tation (WHO) as one of method for medical 
abortion. In 2002, Food and Drug Federation 
(FDA)  was removed  pregnancy from the la-
bel as an absolute contraindication to miso-
prostol use.6
  
CHEMICAL STRUCTURE AND PHARMACO-
KINETIC OF MISOPROSTOL
Misoprostol is a synthetic 15-deoxy-16-
hydroxy-16-methyl analogue of the naturally 
occurring prostaglandin E1. Misoprostol con-
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tains approximately equal amounts of the two 
diastereomers (Figure 1). Misoprostol has 
382.53412 g/mol molecular weight (MW). 
Misoprostol is a water-soluble, viscous liquid. 
Misoprostol is available in either 100 mcg or 
200 mcg tablet dosage forms.1
There is no doses and dosing interval data of 
misoprostol used for any obstetrics gynecol-
ogy  indication that we can find in the FDA 
label of misoprostol because misoprostol is li-
cenced only for treating gastric ulcer. The dos-
es and dosing intervals were usually derived 
empirically from clinical trials. Misoprostol is 
only available in tablet form and  even though 
misoprostol is formulated  for oral use, this 
drug can be absorbed vaginally, sublingually, 
bucally and rectally. One of pharmacokinetic 
study reported oral misoprostol tablet can be 
absorbed by both rectal and vaginal routes 
in early pregnancy. Rectal route absorption 
curve is similar with vaginal route but rectal 
route biovailabilty is lower than vaginal route. 
Misoprostol is absorbed best  when adminis-
trated vaginally.7
BENEFIT OF MISOPROSTOL IN OBSTETRY 
AND GYNECOLOGY PRACTICES
Misoprostol has been extensively stud-
ied in reproductive health. Several studies 
showed misoprostol is very effective for some 
indications such as medical abortion, induc-
tion of labor, postpartum hemorrhage.  
Termination of first and second-trimester 
pregnancy
 World Health Organization (WHO) esti-
mates that 210 million women worldwide 
become pregnant/year and  about two-thirds 
of them deliver live infants. The remaining 
one-third of pregnancies end in miscarriage, 
stillbirth, or induced abortion.8 A medical 
abortion is a way to  end a pregnancy  us-
ing medications. There are several medicine 
which is usually used for medical abortion 
including mifepristone, methotrexate, miso-
prostol and the combination of miferistone 
and misoprostol. Many studies has investigat-
ed effectiveness of misoprostol in medicine 
abortus, especially in a way of  route admin-
istration of misoprostol interest, in which the 
route of administration misoprostol becomes 
important to affect the effectiveness of miso-
prostol. Vaginal administration is the most 
effective followed by sublingual with oral be-
ing the least effective. Sublingual misoprostol 
must be administered more frequent (every 
3 hours) to achieve a similar effectiveness to 
the vaginal route, but sublingual misoprostol 
appears to be more acceptable for women 
requiring treatment for medical abortion.9,10 
Faundes et al reported that the  800 mcg of 
vaginal misoprostol administered every 12 
hours for a maximum of three doses is rec-
ommended for termination of pregnancy up 
to 12 weeks.10 The recommended regimen 
for termination of second trimester pregnan-
cy has been found in a retrospective study in 
which  the regimen of  200 mg oral misopros-
tol at 6-hour intervals following a 200 mg or 
400 mg priming vaginal dose is feasible and 
efficacious for second trimester pregnancy 
termination.11
Misoprostol is not only effective when 
used alone, but misoprostol also effective 
when used with mifepristone to terminate 
early pregnancy. Lin et al12 reported that oral 
mifepristone 200 mg followed by sublingual 
administration of misoprostol 600 μg 48 
hours later resulted in a complete abortion 
rate of 98.5% of pregnancies ≤ 49 days’ ges-
tation, with tolerable side effects and a high 
satisfaction rate of 89.9%.
 One of a prospective observational study 
has concluded that there are several predic-
tors for successful misoprostol therapy for 
early pregnancy failure, such as (1) active 
vaginal bleeding and/or localized abdominal 
cholic, (2) Nulliparity or low parity not more 
than one, (3) Detectable vascularity by color 
doppler imaging (CDI)  in the presumed inter-
villous space  of missed miscarriage or anem-
bryonic pregnancy and avascular trophoblas-
tic tissue of incomplete miscarriage. El khali 
Figure 1 Misoprostol chemical structure1
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et al found evidence that the success rate of 
first-dose of vaginal misoprostol (800 µg) 
may reach >97% in missed miscarriage and 
100% with anembryonic pregnancy in wom-
an with early pregnancy failure  presenting 
with a combination of active vaginal bleeding 
and/or abdominal colic combined with parity 
0–1.13
Induction of labor
Induction of labour is the initiation of la-
bour using artificial means in a pregnant 
women with the aim to achieve vaginal deliv-
ery within 24 to 48 hours.14,15   This is a com-
mon procedure in obstetrics. The indication 
for this procedure including (1) Pregnancy 
beyond term, (2) Prelabour premature ruptur 
of membrane, and (3) Fetal anomaly or fetal 
death.15
There are several methods to promote 
labor induction, including mechanical meth-
ods (eg, membrane stripping or sweeping, 
foley catheter insertion, and amniotomy) and 
pharmacologic agents (eg, oxytocin and pros-
taglandins). Prostaglandin such as misopros-
tol is an agent which has been shown to be 
effective to induction of labour.16 Each dosage 
form of misoprostol has different effective-
ness. Oral misoprostol is more effective than 
placebo and as effective as vaginal misopros-
tol at achieving vaginal delivery.17 As well as 
the dose of misoprostol is still uncertain. A 
meta-analysis has been perfomed by McMas-
ter et al18 to prove the efficacy and safety of 25 
versus 50 micrograms of intravaginal miso-
prostol tablets for the induction of labour and 
cervical ripening. They found evidence that 
the efficacy and safety of 25 micrograms was 
less efficacious than  50 micrograms of vagi-
nal misoprostol when used for labour induc-
tion and cervical ripening. But for the safety 
reasons, the 25-micrograms dose makes pref-
erable.
Postpartum Haemorrhage 
A blood loss of 500 ml or more within 24 
hours after birth is commonly called as post 
partum haemorrhage (PPH). PPH is the lead-
ing cause of maternal mortality in low-income 
countries and the primary cause of nearly one 
quarter of all maternal deaths globally. PPH is 
the most leading cause of death and the ma-
jority of these could be avoided through the 
use of prophylactic uterotonics during the 
third stage of labour.19 
Active management of  the third stage of 
labour which consist  prophylactic adminis-
tration of a uterotonic agent, controlled trac-
tion of the umbilical cord, and uterine mas-
sage is highly effective to reduce the risk of 
PPH. Uterotonic agents such as oxytocin are 
administered shortly following delivery of the 
baby to stimulate uterine contractions.  WHO 
has recommended the use of  oxytocin 10 IU 
as uterotonic agents during the third stage of 
labor for the prevention of PPH for all births. 
Oxytocin has been used routinely during ce-
sarean delivery to prevent uterine atony and 
excessive uterine bleeding.  Unfortunately, 
oxytocin is only available in injection form 
which is seldom available for births outside 
the health system, therefore misoprostol has 
attracted attention to prevent or treat post-
partum haemorrhage.20
Risk of Misoprostol in Obstetry and Gyne-
cology Practices
Eventhough misoprostol has so many 
benefit in obstetrics and gynecology field, 
misoprostol has many undesirable effects. 
Several case study of misoprostol side effect 
were reported by researchers worldwide. 
Schoen et al21 reported A 21-year-old woman 
received buccal misoprostol as a ripening agent 
for postdate labor induction and experienced 
anaphylaxis and tachysystole. Misoprostol 
can cause high fevers and there is an evidence 
that genetic susceptibility may play role in 
misoprostol-induced fever.  Alvirefic et al22 
reported the role of genetic in misoprostol 
induced-fever. They found that The ABCC4 
single nucleotide polymorphism rs11568658 
may contribute with misoprostol-induced 
fever.
Induction with misoprostol is one of risk 
factors for uterine rupture even in women 
with no prior cesarean delivery history. A 
case study which is reported by Mazzone and 
Woolever23 found that a multigravida wom-
an  had a spontaneous uterine rupture af-
ter induction with misoprostol and oxytocin 
eventhough she did not have an unscarred 
uterus. Nuthalapaty et al 24  found that high 
dose vaginal misoprostol (an initial 600 μg 
dose of intravaginal misoprostol followed by 
an additional 400 μg of intravaginal miso-
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prostol every 4 hours) can cause side effects 
including post partum hemorrhage (> 500 cc), 
isolated fever, nausea and diarrhea  higher 
than woman who received concentrated oxy-
tocin plus low-dose vaginal PGE1 (277-1667 
mU/min dose of oxytocin plus vaginal miso-
prostol 400 μg initially, followed by 200 μg 
every 6 hours for 2 doses, then 100 μg for one 
dose (total 900 μg)). Another study reported 
incidence of side effects following misopros-
tol treatment according to gestational age at 
abortion. That study found that there are dif-
ference proportion of side effects between ≤ 
12 weeks of pregnancy with up to 12 weeks of 
pregnancy. Less than 10% of the women with 
≤ 12 weeks reported side effects, which con-
sisted of severe pain, chills, fever and diarh-
hea. In contrast with woman with ≥ 12 weeks 
who have  high side effect proportion.25
In cases of retained placenta, high dose 
misoprostol administered rectally does not 
give a promising result to expulsion of placen-
ta within 30 minutes after rectal misoprostol 
administration and does not seem to decrease 
the rate of manual remove of placenta (MROP) 
under general anethesia.26
A case of severe hypersensitivity reaction 
after treatment with intravaginal adminis-
tration of misoprostol has been reported. 
Madaan et al27 reported a 32 year primigrav-
ida presented at 12 weeks of gestation with 
missed abortion who received intravaginal 
misoprostol 800μg experiences  severe hy-
persensitivity reaction which begins with 
sympotoms such as shivering, intense burn-
ing sensation and feeling of warmth over face, 
hands and feet after 20 minutes of intravagi-
nal placement of misoprostol. This case must 
be kept in mind that hat the use of misopros-
tol does not rule out the possibility of the 
emergence of side effects.
CONCLUSIONS
Although misoprostol is not licensed for 
reproductive health use , it is widely used by 
gynecologist and obstetricians. Misoprostol 
has been proven to have numerous beneficial 
effects, including the ability to prevent and 
treat postpartum hemorrhage and to induce 
labor. However, every drugs has side effects so 
that needs to be used with care and based on 
evidence based medicine.
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